APRE on Nasdaq
Aprea Therapeutics, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Grant revenue | $285.8K | $1.5M |
| Research and development | $7.0M | $9.4M |
| General and administrative | $6.5M | $6.5M |
| Total operating expenses | $13.5M | $15.8M |
| Loss from operations | -$13.2M | -$14.3M |
| Interest income, net | $652.1K | $1.3M |
| Other income | $77.5K | |
| Foreign currency (loss) gain | -$95.3K | $71.8K |
| Total other income | $634.3K | $1.4M |
| Net loss | -$12.6M | -$13.0M |
| Foreign currency translation | -$7.3K | -$16.1K |
| Total comprehensive loss | -$12.6M | -$13.0M |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -$1.93 | -$2.35 |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -$1.93 | -$2.35 |
| Weighted-average common shares outstanding, basic (in shares) | 6.5M shares | 5.5M shares |
| Weighted-average common shares outstanding, diluted (in shares) | 6.5M shares | 5.5M shares |
Every line of the balance sheet in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $14.6M | $22.8M | |
| Prepaid expenses and other current assets | $961.9K | $726.3K | |
| Total current assets | $15.6M | $23.6M | |
| Property and equipment, net | $59.8K | $81.5K | |
| Restricted cash | $41.2K | $40.2K | |
| Other noncurrent assets | $271.2K | $281.7K | |
| Total assets | $15.9M | $24.0M | |
| Accounts payable | $713.7K | $1.4M | |
| Accrued expenses | $2.1M | $2.0M | |
| Total current liabilities | $2.8M | $3.4M | |
| Common stock, $0.001 par value, 400,000,000 shares authorized, 8,192,538 and 5,481,055 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $8.2K | $5.5K | |
| Additional paid-in capital | $356.7M | $351.0M | |
| Accumulated other comprehensive loss | -$10.6M | -$10.6M | |
| Accumulated deficit | -$333.6M | -$321.0M | |
| Total stockholders' equity | $12.4M | $19.3M | $17.0M |
| Total liabilities and stockholders' equity | $15.9M | $24.0M | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized | 400.0M shares | 400.0M shares | |
| Common stock, shares issued | 8.2M shares | 5.5M shares | |
| Common stock, shares outstanding | 8.2M shares | 5.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$12.6M | -$13.0M |
| Depreciation and amortization | $21.7K | $22.3K |
| Stockbased compensation | $478.1K | $489.4K |
| Issuance of common stock to consultants | $39.0K | $17.4K |
| Foreign currency loss (gain) | $95.3K | -$71.8K |
| Prepaid expenses and other current and noncurrent assets | -$217.9K | -$96.7K |
| Accounts payable | -$646.7K | -$314.2K |
| Accrued expenses | -$64.5K | -$115.5K |
| Deferred grant revenue | -$529.0K | |
| Net cash used in operating activities | -$12.9M | -$13.6M |
| Purchases of property and equipment | -$15.5K | |
| Net cash used in investing activities | -$15.5K | |
| Proceeds from the exercise of warrants | $91 | |
| Proceeds from issuance of common stock | $5.0M | $16.1M |
| Common stock issuance costs | -$407.5K | -$1.3M |
| Net cash provided by financing activities | $4.6M | $14.8M |
| Change in cash, cash equivalents and restricted cash | -$8.3M | $1.2M |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | $4.7K | -$7.2K |
| Conversion of Series A convertible preferred stock to common stock | $583.7K |
Recent filings
- Aug 28, 20268-K
- Aug 13, 2026SCHEDULE 13G/A
- Aug 12, 20268-K
- Aug 12, 202610-Q
- Jul 23, 20268-K
- Jun 17, 20268-K
- Jun 17, 20264 OWNERSHIP DOCUMENT
- Jun 17, 20264 OWNERSHIP DOCUMENT
- Jun 17, 20264 OWNERSHIP DOCUMENT
- Jun 17, 20264 OWNERSHIP DOCUMENT
- Jun 17, 20264 OWNERSHIP DOCUMENT
- Jun 17, 20264 OWNERSHIP DOCUMENT
- Jun 17, 20264 OWNERSHIP DOCUMENT
- Jun 17, 20264 OWNERSHIP DOCUMENT
- May 15, 2026424B7
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10